Sees FY24 product revenues, net $138.0M-$158.0M; and adjusted Operating Expenses, excluding stock-based compensation and depreciation and amortization $108.0M-$116.0M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRTX:
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
- Biotech Alert: Searches spiking for these stocks today
- Heron Therapeutics management to meet virtually with Northland
- Heron Therapeutics initiated with an Overweight at Capital One
- Heron Therapeutics Announces New Principal Accounting Officer